Abstract:
Background: A definitive treatment of SARS CoV-2 is yet to
arrive and the human death toll rises exponentially globally.
In this health emergency, it might be useful to look into the
old therapies which could be effective against the virus. In
vitro research showed Ivermectin could decrease the
concentration of coronavirus 4000 to 5000 folds in living
lung tissue.
Aim: In this prospective study a combination of Ivermectin
and Doxycycline will be evaluated therapeutically to treat
COVID-19 patients.
Methods: 100 COVID-19 patients were enrolled in this study
with a predefined inclusion and exclusion criteria. RT- PCR
of the SERS-CoV-2 will be done at designated government
hospitals. The clinical features and response to treatment
were noted according to a dedicated protocol.
Results: In this study male and female were 64 and 36
respectively, the age ranged between 8 to 84 years. Retesting
was done between 4 and 18 days of starting medication. All
patients tested negative and their symptoms improved within
72 hours. There were no noticeable side effects.
Conclusion: Combination of Ivermectin and doxycycline
was found to be very effective in viral clearance in mild and
moderately sick COVID-19 patients. Medical societies and
institutions should undertake larger multi center studies to
validate and recommend this combination therapy to include
in national guidelines.
Keywords: Covid-19, Doxycycline, Ivermectin
Bangladesh Coll Phys Surg 2020; 38: 10-15)
DOI: https://doi.org/10.3329/jbcps.v38i0.47512